Company news

Vanda Pharmaceuticals Inc. news in 2026

Vanda Pharmaceuticals Inc.'s news releases, calls and decks from 2026, newest first.

View company

Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences

November 3, 2026

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results

October 28, 2026

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting

October 27, 2026

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

October 21, 2026

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

October 14, 2026

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

October 2, 2026

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

September 29, 2026

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

September 2, 2026

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

August 24, 2026

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

August 22, 2026

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 5, 2026

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

July 29, 2026

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

July 16, 2026

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

July 15, 2026

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

July 10, 2026

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

July 7, 2026

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

May 26, 2026

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

May 7, 2026

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

May 5, 2026

Model N Appoints Thomas Gibbs to Board of Directors

May 5, 2026

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

May 1, 2026

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

April 29, 2026

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

April 28, 2026

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

April 22, 2026

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

April 9, 2026

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

April 7, 2026

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

March 19, 2026

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

March 2, 2026

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

February 26, 2026

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

February 25, 2026

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

February 19, 2026

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

February 11, 2026

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

February 4, 2026

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

January 7, 2026

Calls in 2026

Decks in 2026